论文部分内容阅读
采用Ortho抗-HCV C100-3试剂检测了61例重症乙型肝炎,66例轻型慢性乙肝和22例多次受血治疗的非肝脏疾病患者血清中抗HCV C100-3抗体。重症肝炎中,抗-HCV检出率(36.07％)不仅明显高于轻型慢性乙肝组(4.55％),也高于受血治疗组(13.64％);对比分析重症肝炎HBV/HCV双重感染组与单纯HBV感染组的总胆红素、AST/ALT比值及病死率的结果,两组有显著性差异(P<0.05),提示重症肝炎患者由于多次受血治疗及肝脏本身的严重病变,因而对HCV的易感性较高;HBV/HCV双重感染可能加剧了肝脏的损害,加速了肝炎重症化的进程。
The anti-HCV C100-3 antibody in sera of 61 patients with severe hepatitis B, 66 patients with mild chronic hepatitis B and 22 patients receiving multiple blood transfusions was tested using the Ortho anti-HCV C100-3 reagent. Severe hepatitis, anti-HCV detection rate (36.07%) was not only significantly higher than the light chronic hepatitis B (4.55%), also higher than the blood treatment group (13.64%); comparative analysis of severe hepatitis HBV / HCV double infection and The result of total bilirubin, AST / ALT ratio and mortality in patients with HBV infection showed significant difference between the two groups (P <0.05), suggesting that patients with severe hepatitis due to multiple blood transfusions and severe liver disease, thus High susceptibility to HCV; HBV / HCV double infection may exacerbate the liver damage, accelerated the process of severe hepatitis.